Ozempic, and other GLP-1 drugs like Wegovy and Rybelsus manufactured by Novo Nordisk and Trulicity, Mounjaro, and Zepbound manufactured by Eli Lilly work by mimicking the effects of the incretin glucagon-like peptide-1 (GLP-1) to regulate blood sugar levels in diabetic patients. Administered via an injector pen on a weekly basis, Ozempic helps control high blood sugar by limiting excess sugar production in the liver and stimulating insulin production in the pancreas.
While effective for many in managing diabetes and weight loss, some patients have experienced severe side effects such as stomach paralysis, gastroparesis, bowel obstruction (referred to as ileus or intestinal blockage), pulmonary aspiration, deep vein thrombosis, and gallbladder disease. These gastrointestinal issues, linked to long-term use of high doses of Ozempic for weight loss, have led to lawsuits across the country. SLG’s Marcus Susen was recently appointed by the Court overseeing this consolidated litigation to help lead the litigation on behalf of all plaintiffs.
Injuries linked to this Ozempic:
- Gastroparesis / Stomach Paralysis
- Bowel Obstruction / Ileus
- Pulmonary Aspiration
- Deep Vein Thrombosis
- Gallbladder Removal
- Hospitalization
- Death
There are currently over 11,000 FDA adverse events reported to the FDA with the FDA also recognizing that only 1-10% of adverse events ever get reported. Using this fact, there are likely over 100,000 adverse events associated with these drugs.
While all medications can have adverse effects, drug manufacturers are required by law to inform consumers about potential risks. The ongoing lawsuits against Novo Nordisk and Eli Lilly claim that the company did not adequately warn healthcare providers and patients about possible side effects like stomach paralysis, gastroparesis, bowel obstruction (referred to as ileus or intestinal blockage), pulmonary aspiration, deep vein thrombosis, and gallbladder disease.